Clinicopathological features of adult T-cell leukemia/lymphoma with HTLV-1-infected Hodgkin and Reed-Sternberg-like cells.


Journal

Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425

Informations de publication

Date de publication:
12 01 2021
Historique:
received: 17 08 2020
accepted: 20 11 2020
entrez: 11 2 2021
pubmed: 12 2 2021
medline: 15 5 2021
Statut: ppublish

Résumé

Hodgkin and Reed-Sternberg (HRS) cells, a hallmark of classic Hodgkin lymphoma (CHL), are occasionally detected in non-Hodgkin lymphomas, including adult T-cell leukemia/lymphoma (ATLL), a lymphoid neoplasm caused by human T-cell leukemia virus type 1 (HTLV-1). HRS-like cells associated with ATLL have been described to be of B-cell lineage and infected with Epstein-Barr virus (EBV), not HTLV-1. We herein describe clinicopathological findings in 8 cases (4 males and 4 females; median age, 73 years [range, 55-81 years]) of ATLL with HTLV-1-infected HRS-like cells identified by ultrasensitive RNA in situ hybridization for HTLV-1 basic leucine zipper factor (HBZ-ISH), a specific viral transcript of HTLV-1. All patients showed nodal or mediastinal lesions, and 5 of the 8 patients were at an advanced disease stage. HRS-like cells were positive for CD30, CD15, MUM1, CD25, and HBZ-ISH and negative for B-cell markers, including PAX5, pan-T-cell antigens, and EBV in all cases. Five cases were positive for CD4, and 6 cases were positive for fascin. HBZ was identified in both HRS-like cells and surrounding lymphoid cells in 1 case with an aggressive clinical course and only HRS-like cells in 7 cases, most of whom showed a clinical response regardless of the chemotherapeutic regimen. Even though the definitive lineage typing of the HTLV-1-infected HRS cells is one of the limitations of this study in the absence of single-cell microdissection for polymerase chain reaction analysis, the combination of diffuse HBZ-ISH positivity and negativity for PAX5 and EBV deemed these cases distinct from CHL arising in HTLV-1 carriers.

Identifiants

pubmed: 33570645
pii: S2473-9529(21)00019-7
doi: 10.1182/bloodadvances.2020003201
pmc: PMC7805330
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

198-206

Informations de copyright

© 2021 by The American Society of Hematology.

Références

Cancer. 1991 Mar 15;67(6):1622-8
pubmed: 2001551
Am J Surg Pathol. 2019 Dec;43(12):1611-1621
pubmed: 31305266
Am J Surg Pathol. 2010 Sep;34(9):1382-7
pubmed: 20739840
Proc Natl Acad Sci U S A. 1984 Apr;81(8):2534-7
pubmed: 6326131
Blood. 2000 May 15;95(10):3020-4
pubmed: 10807764
J Clin Oncol. 2012 May 10;30(14):1635-40
pubmed: 22473153
Am J Surg Pathol. 2003 Dec;27(12):1513-22
pubmed: 14657710
Mod Pathol. 2008 May;21(5):617-25
pubmed: 18246047
Cancer Sci. 2007 Jun;98(6):772-8
pubmed: 17388788
Br J Haematol. 1991 Nov;79(3):428-37
pubmed: 1751370
Mod Pathol. 2011 Aug;24(8):1046-54
pubmed: 21499229
Am J Surg Pathol. 2007 Feb;31(2):216-23
pubmed: 17255766
Diagn Mol Pathol. 2002 Jun;11(2):83-9
pubmed: 12045711
Am J Surg Pathol. 1999 Oct;23(10):1233-40
pubmed: 10524524
Br J Haematol. 2014 Sep;166(5):739-48
pubmed: 24931507
Mod Pathol. 2021 Jan;34(1):51-58
pubmed: 32801340
Cancer Sci. 2019 Sep;110(9):2982-2991
pubmed: 31237072
J Exp Med. 2000 Jan 17;191(2):387-94
pubmed: 10637283
Am J Surg Pathol. 2012 Dec;36(12):1874-82
pubmed: 23060353
Int J Cancer. 1997 Aug 7;72(4):592-8
pubmed: 9259396
Leukemia. 2003 Dec;17(12):2257-317
pubmed: 14671650
Blood. 2020 Jul 9;136(2):257
pubmed: 32645171
Mod Pathol. 2018 Jul;31(7):1046-1063
pubmed: 29449683
Histopathology. 2012 Apr;60(5):768-73
pubmed: 22296097
Braz J Infect Dis. 2017 Jan - Feb;21(1):119-122
pubmed: 27789281
Blood. 2013 Mar 7;121(10):1795-804
pubmed: 23305738
Am J Surg Pathol. 2012 Nov;36(11):1636-46
pubmed: 23073322
Blood. 2013 Oct 17;122(16):2856-63
pubmed: 24004665
Histopathology. 2020 Jul;77(1):133-143
pubmed: 32162348
Hum Pathol. 2011 Jul;42(7):1042-6
pubmed: 21315416

Auteurs

Kennosuke Karube (K)

Department of Pathology and Cell Biology, Graduate School of Medicine, University of the Ryukyus, Nishihara, Japan.

Mitsuyoshi Takatori (M)

Department of Pathology and Cell Biology, Graduate School of Medicine, University of the Ryukyus, Nishihara, Japan.

Shugo Sakihama (S)

Department of Pathology and Cell Biology, Graduate School of Medicine, University of the Ryukyus, Nishihara, Japan.

Yuma Tsuruta (Y)

Department of Pathology and.

Takashi Miyagi (T)

Department of Hematology, Heartlife Hospital, Nakagusuku, Japan.

Kazuho Morichika (K)

Division of Endocrinology, Diabetes and Metabolism, Hematology, and Rheumatology (Second Department of Internal Medicine), Graduate School of Medicine, University of the Ryukyus, Nishihara, Japan.

Sakiko Kitamura (S)

Division of Endocrinology, Diabetes and Metabolism, Hematology, and Rheumatology (Second Department of Internal Medicine), Graduate School of Medicine, University of the Ryukyus, Nishihara, Japan.

Norihiro Nakada (N)

Department of Pathology and.

Masaki Hayashi (M)

Department of Hematology, Nakagami Hospital, Okinawa City, Japan.

Shohei Tomori (S)

Department of Hematology, Nakagami Hospital, Okinawa City, Japan.

Iwao Nakazato (I)

Department of Pathology and.

Kazuiku Ohshiro (K)

Department of Hematology, Okinawa Prefectural Nanbu Medical Center and Children's Medical Center, Haebaru, Japan.

Naoki Imaizumi (N)

Laboratory of Molecular Genetics, School of Health Sciences, Faculty of Medicine, University of the Ryukyus, Nishihara, Japan.

Yara Yukie Kikuti (YY)

Department of Pathology, Tokai University School of Medicine, Isehara, Japan; and.

Naoya Nakamura (N)

Department of Pathology, Tokai University School of Medicine, Isehara, Japan; and.

Satoko Morishima (S)

Division of Endocrinology, Diabetes and Metabolism, Hematology, and Rheumatology (Second Department of Internal Medicine), Graduate School of Medicine, University of the Ryukyus, Nishihara, Japan.

Hiroaki Masuzaki (H)

Division of Endocrinology, Diabetes and Metabolism, Hematology, and Rheumatology (Second Department of Internal Medicine), Graduate School of Medicine, University of the Ryukyus, Nishihara, Japan.

Takuya Fukushima (T)

Laboratory of Hematoimmunology, School of Health Sciences, Faculty of Medicine, University of the Ryukyus, Nishihara, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH